The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century
- PMID: 25852053
- PMCID: PMC4440879
- DOI: 10.1182/blood-2014-10-567784
The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century
Abstract
The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell transplantation (SCT). Nevertheless, SCT still remains an option for accelerated/blastic-phase and selected chronic-phase CML. Transplant outcomes can be optimized by peritransplant TKIs, conditioning regimen, BCR-ABL monitoring, and relapse management. Controversies exist in transplant timing, pediatric CML, alternative donors, and economics. SCT continues to serve as a platform of "operational cure" for CML with TKIs and immunotherapies.
References
-
- Buckner CD, Clift RA, Fefer A, Neiman PE, Storb R, Thomas ED. Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol. 1974;2(3):138–146. - PubMed
-
- Buckner CD, Stewart P, Clift RA, et al. Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol. 1978;6(1):96–109. - PubMed
-
- Fefer A, Cheever MA, Thomas ED, et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med. 1979;300(7):333–337. - PubMed
-
- Clift RA, Buckner CD, Thomas ED, et al. Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet. 1982;320(8299):621–623. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
